APO Research
Talk to an analyst

APO RESEARCH · REPORT

Systemic Aspergillosis and Systemic Candidasis

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Systemic Aspergillosis and Systemic Candidasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025180 pages

Choose your research edition.

Industry ResearchSystemic Aspergillosis and Systemic Candidasis Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Systemic Aspergillosis and Systemic Candidasis Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Systemic Aspergillosis and Systemic Candidasis Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Systemic Aspergillosis and Systemic Candidasis Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Systemic Aspergillosis and Systemic Candidasis Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Systemic Aspergillosis and Systemic Candidasis market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Systemic Aspergillosis and Systemic Candidasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Systemic Aspergillosis and Systemic Candidasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Systemic Aspergillosis and Systemic Candidasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Systemic Aspergillosis and Systemic Candidasis is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Systemic Aspergillosis and Systemic Candidasis include Abbott, Novartis AG, Merck & Co., Inc, Pfizer, Inc, GlaxoSmithKline plc, Bayer AG, Sanofi-Aventis, Enzon Pharmaceuticals, Inc and Astellas Pharma, Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Systemic Aspergillosis and Systemic Candidasis market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Systemic Aspergillosis and Systemic Candidasis and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Systemic Aspergillosis and Systemic Candidasis sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Systemic Aspergillosis and Systemic Candidasis market size, projected growth trends, production technologies, key applications, and end-use industries.

Systemic Aspergillosis and Systemic Candidasis Segment by Company

Abbott

Novartis AG

Merck & Co., Inc

Pfizer, Inc

GlaxoSmithKline plc

Bayer AG

Sanofi-Aventis

Enzon Pharmaceuticals, Inc

Astellas Pharma, Inc

Systemic Aspergillosis and Systemic Candidasis Segment by Type

Liposomal Amphotericin B

Systemic Oral Azoles

Topical Antifungal Agents

Voriconazole

Other

Systemic Aspergillosis and Systemic Candidasis Segment by Application

Gastrointestinal Candidiasis

Genitourinary Tract Candidiasis

CPA

ABPA

Other

Systemic Aspergillosis and Systemic Candidasis Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Systemic Aspergillosis and Systemic Candidasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Systemic Aspergillosis and Systemic Candidasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Systemic Aspergillosis and Systemic Candidasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Systemic Aspergillosis and Systemic Candidasis market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Systemic Aspergillosis and Systemic Candidasis manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Systemic Aspergillosis and Systemic Candidasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Systemic Aspergillosis and Systemic Candidasis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Systemic Aspergillosis and Systemic Candidasis Industry Trends Table 2. Systemic Aspergillosis and Systemic Candidasis Industry Drivers Table 3. Systemic Aspergillosis and Systemic Candidasis Industry Opportunities and Challenges Table 4. Systemic Aspergillosis and Systemic Candidasis Industry Restraints Table 5. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Systemic Aspergillosis and Systemic Candidasis Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Manufacturers Table 9. Global Systemic Aspergillosis and Systemic Candidasis Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Systemic Aspergillosis and Systemic Candidasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Systemic Aspergillosis and Systemic Candidasis Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Systemic Aspergillosis and Systemic Candidasis Manufacturers, Product Type & Application Table 13. Global Systemic Aspergillosis and Systemic Candidasis Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Systemic Aspergillosis and Systemic Candidasis by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Liposomal Amphotericin B Table 17. Major Manufacturers of Systemic Oral Azoles Table 18. Major Manufacturers of Topical Antifungal Agents Table 19. Major Manufacturers of Voriconazole Table 20. Major Manufacturers of Other Table 21. Global Systemic Aspergillosis and Systemic Candidasis Sales by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021-2026) & (k units) Table 23. Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2027-2032) & (k units) Table 24. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Type (2021-2026) Table 25. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Type (2027-2032) Table 26. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 27. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type (2021-2026) & (k units) Table 28. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type (2027-2032) & (k units) Table 29. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Type (2021-2026) Table 30. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Gastrointestinal Candidiasis Table 32. Major Manufacturers of Genitourinary Tract Candidiasis Table 33. Major Manufacturers of CPA Table 34. Major Manufacturers of ABPA Table 35. Major Manufacturers of Other Table 36. Global Systemic Aspergillosis and Systemic Candidasis Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021-2026) & (k units) Table 38. Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2027-2032) & (k units) Table 39. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Application (2021-2026) Table 40. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Application (2027-2032) Table 41. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application (2021-2026) & (k units) Table 43. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application (2027-2032) & (k units) Table 44. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Application (2021-2026) Table 45. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Application (2027-2032) Table 46. Global Systemic Aspergillosis and Systemic Candidasis Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Systemic Aspergillosis and Systemic Candidasis Sales by Region (2021-2026) & (k units) Table 48. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Region (2021-2026) Table 49. Global Systemic Aspergillosis and Systemic Candidasis Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Systemic Aspergillosis and Systemic Candidasis Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2026) & (k units) Table 53. North America Systemic Aspergillosis and Systemic Candidasis Sales by Country (2027-2032) & (k units) Table 54. Europe Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2026) & (k units) Table 56. Europe Systemic Aspergillosis and Systemic Candidasis Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales by Country (2027-2032) & (k units) Table 63. Global Systemic Aspergillosis and Systemic Candidasis Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Region (2021-2026) Table 67. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Region (2027-2032) Table 68. Abbott Company Information Table 69. Abbott Business Overview Table 70. Abbott Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Abbott Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 72. Abbott Recent Development Table 73. Novartis AG Company Information Table 74. Novartis AG Business Overview Table 75. Novartis AG Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Novartis AG Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 77. Novartis AG Recent Development Table 78. Merck & Co., Inc Company Information Table 79. Merck & Co., Inc Business Overview Table 80. Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 82. Merck & Co., Inc Recent Development Table 83. Pfizer, Inc Company Information Table 84. Pfizer, Inc Business Overview Table 85. Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 87. Pfizer, Inc Recent Development Table 88. GlaxoSmithKline plc Company Information Table 89. GlaxoSmithKline plc Business Overview Table 90. GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 92. GlaxoSmithKline plc Recent Development Table 93. Bayer AG Company Information Table 94. Bayer AG Business Overview Table 95. Bayer AG Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Bayer AG Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 97. Bayer AG Recent Development Table 98. Sanofi-Aventis Company Information Table 99. Sanofi-Aventis Business Overview Table 100. Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 102. Sanofi-Aventis Recent Development Table 103. Enzon Pharmaceuticals, Inc Company Information Table 104. Enzon Pharmaceuticals, Inc Business Overview Table 105. Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 107. Enzon Pharmaceuticals, Inc Recent Development Table 108. Astellas Pharma, Inc Company Information Table 109. Astellas Pharma, Inc Business Overview Table 110. Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio Table 112. Astellas Pharma, Inc Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Systemic Aspergillosis and Systemic Candidasis Distributors List Table 116. Systemic Aspergillosis and Systemic Candidasis Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Systemic Aspergillosis and Systemic Candidasis Product Image Figure 2. Global Systemic Aspergillosis and Systemic Candidasis Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Systemic Aspergillosis and Systemic Candidasis Market Size (2021-2032) & (US$ Million) Figure 4. Global Systemic Aspergillosis and Systemic Candidasis Sales (2021-2032) & (k units) Figure 5. Global Systemic Aspergillosis and Systemic Candidasis Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Systemic Aspergillosis and Systemic Candidasis Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Liposomal Amphotericin B Image Figure 9. Systemic Oral Azoles Image Figure 10. Topical Antifungal Agents Image Figure 11. Voriconazole Image Figure 12. Other Image Figure 13. Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Type (2021-2032) Figure 16. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 17. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Type (2021-2032) Figure 19. Gastrointestinal Candidiasis Image Figure 20. Genitourinary Tract Candidiasis Image Figure 21. CPA Image Figure 22. ABPA Image Figure 23. Other Image Figure 24. Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Application (2021-2032) Figure 27. Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Application (2021-2032) Figure 30. North America Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Country (2021-2032) Figure 32. U.S. Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Country (2021-2032) Figure 37. Germany Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Country (2021-2032) Figure 44. China Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Country (2021-2032) Figure 52. Brazil Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Systemic Aspergillosis and Systemic Candidasis Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Systemic Aspergillosis and Systemic Candidasis Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032) & (US$ Million) Figure 63. North America Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032) & (US$ Million) Figure 65. Europe Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Systemic Aspergillosis and Systemic Candidasis Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Systemic Aspergillosis and Systemic Candidasis Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Liposomal Amphotericin B
  • Systemic Oral Azoles
  • Topical Antifungal Agents
  • Voriconazole
  • Other
Applications
  • Gastrointestinal Candidiasis
  • Genitourinary Tract Candidiasis
  • CPA
  • ABPA
  • Other
Companies covered
  • Abbott
  • Novartis AG
  • Merck & Co., Inc
  • Pfizer, Inc
  • GlaxoSmithKline plc
  • Bayer AG
  • Sanofi-Aventis
  • Enzon Pharmaceuticals, Inc
  • Astellas Pharma, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Systemic Aspergillosis and Systemic Candidasis Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Systemic Aspergillosis and Systemic Candidasis Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Systemic Aspergillosis and Systemic Candidasis Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Systemic Aspergillosis and Systemic Candidasis Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Systemic Aspergillosis and Systemic Candidasis Market Dynamics
  1. 2.1 Systemic Aspergillosis and Systemic Candidasis Industry Trends
  2. 2.2 Systemic Aspergillosis and Systemic Candidasis Industry Drivers
  3. 2.3 Systemic Aspergillosis and Systemic Candidasis Industry Opportunities and Challenges
  4. 2.4 Systemic Aspergillosis and Systemic Candidasis Industry Restraints
3 Systemic Aspergillosis and Systemic Candidasis Market by Manufacturers
  1. 3.1 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Manufacturers (2021-2026)
  3. 3.3 Global Systemic Aspergillosis and Systemic Candidasis Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Systemic Aspergillosis and Systemic Candidasis Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Systemic Aspergillosis and Systemic Candidasis Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Systemic Aspergillosis and Systemic Candidasis Manufacturers, Product Type & Application
  7. 3.7 Global Systemic Aspergillosis and Systemic Candidasis Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Systemic Aspergillosis and Systemic Candidasis Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Systemic Aspergillosis and Systemic Candidasis Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Systemic Aspergillosis and Systemic Candidasis Tier 1, Tier 2, and Tier 3
4 Systemic Aspergillosis and Systemic Candidasis Market by Type
  1. 4.1 Systemic Aspergillosis and Systemic Candidasis Type Introduction
  2. 4.1.1 Liposomal Amphotericin B
  3. 4.1.2 Systemic Oral Azoles
  4. 4.1.3 Topical Antifungal Agents
  5. 4.1.4 Voriconazole
  6. 4.1.5 Other
  7. 4.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Type
  8. 4.2.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Type (2021-2032)
  10. 4.2.3 Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Type (2021-2032)
  11. 4.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type
  12. 4.3.1 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Type (2021-2032)
  14. 4.3.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Type (2021-2032)
5 Systemic Aspergillosis and Systemic Candidasis Market by Application
  1. 5.1 Systemic Aspergillosis and Systemic Candidasis Application Introduction
  2. 5.1.1 Gastrointestinal Candidiasis
  3. 5.1.2 Genitourinary Tract Candidiasis
  4. 5.1.3 CPA
  5. 5.1.4 ABPA
  6. 5.1.5 Other
  7. 5.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Application
  8. 5.2.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Application (2021-2032)
  10. 5.2.3 Global Systemic Aspergillosis and Systemic Candidasis Sales Market Share by Application (2021-2032)
  11. 5.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application
  12. 5.3.1 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Application (2021-2032)
  14. 5.3.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Application (2021-2032)
6 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region
  1. 6.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region (2021-2032)
  3. 6.2.1 Global Systemic Aspergillosis and Systemic Candidasis Sales by Region (2021-2026)
  4. 6.2.2 Global Systemic Aspergillosis and Systemic Candidasis Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region
  1. 7.1 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region
  2. 7.1.1 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region (2021-2026)
  4. 7.1.3 Global Systemic Aspergillosis and Systemic Candidasis Revenue by Region (2027-2032)
  5. 7.1.4 Global Systemic Aspergillosis and Systemic Candidasis Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032)
  8. 7.2.2 North America Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032)
  11. 7.3.2 Europe Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Systemic Aspergillosis and Systemic Candidasis Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Novartis AG
  8. 8.2.1 Novartis AG Company Information
  9. 8.2.2 Novartis AG Business Overview
  10. 8.2.3 Novartis AG Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis AG Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  12. 8.2.5 Novartis AG Recent Developments
  13. 8.3 Merck & Co., Inc
  14. 8.3.1 Merck & Co., Inc Company Information
  15. 8.3.2 Merck & Co., Inc Business Overview
  16. 8.3.3 Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Merck & Co., Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  18. 8.3.5 Merck & Co., Inc Recent Developments
  19. 8.4 Pfizer, Inc
  20. 8.4.1 Pfizer, Inc Company Information
  21. 8.4.2 Pfizer, Inc Business Overview
  22. 8.4.3 Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  24. 8.4.5 Pfizer, Inc Recent Developments
  25. 8.5 GlaxoSmithKline plc
  26. 8.5.1 GlaxoSmithKline plc Company Information
  27. 8.5.2 GlaxoSmithKline plc Business Overview
  28. 8.5.3 GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline plc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  30. 8.5.5 GlaxoSmithKline plc Recent Developments
  31. 8.6 Bayer AG
  32. 8.6.1 Bayer AG Company Information
  33. 8.6.2 Bayer AG Business Overview
  34. 8.6.3 Bayer AG Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer AG Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  36. 8.6.5 Bayer AG Recent Developments
  37. 8.7 Sanofi-Aventis
  38. 8.7.1 Sanofi-Aventis Company Information
  39. 8.7.2 Sanofi-Aventis Business Overview
  40. 8.7.3 Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sanofi-Aventis Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  42. 8.7.5 Sanofi-Aventis Recent Developments
  43. 8.8 Enzon Pharmaceuticals, Inc
  44. 8.8.1 Enzon Pharmaceuticals, Inc Company Information
  45. 8.8.2 Enzon Pharmaceuticals, Inc Business Overview
  46. 8.8.3 Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Enzon Pharmaceuticals, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  48. 8.8.5 Enzon Pharmaceuticals, Inc Recent Developments
  49. 8.9 Astellas Pharma, Inc
  50. 8.9.1 Astellas Pharma, Inc Company Information
  51. 8.9.2 Astellas Pharma, Inc Business Overview
  52. 8.9.3 Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Astellas Pharma, Inc Systemic Aspergillosis and Systemic Candidasis Product Portfolio
  54. 8.9.5 Astellas Pharma, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Systemic Aspergillosis and Systemic Candidasis Value Chain Analysis
  2. 9.1.1 Systemic Aspergillosis and Systemic Candidasis Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Systemic Aspergillosis and Systemic Candidasis Production Mode & Process
  6. 9.2 Systemic Aspergillosis and Systemic Candidasis Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Systemic Aspergillosis and Systemic Candidasis Distributors
  9. 9.2.3 Systemic Aspergillosis and Systemic Candidasis Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst